Results 201 to 210 of about 31,601 (273)

A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients

, 2019
Feng Tian, Jingyang Li, Zhenhua Wen, Xiao‐Wen Luo, Li Deng, Liang Zhang, Jingyun He   +6 more
openalex   +1 more source

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]

BioDrugs
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG.   +5 more
europepmc   +1 more source

Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma. [PDF]

Medicine (Baltimore)
Yang J, Xu Q, Wu S.
europepmc   +1 more source

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. [PDF]

Front Pharmacol
Song Y, Shin G, Choi G, Han E, Ou HT, Bae S.   +5 more
europepmc   +1 more source

Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

, 2018
Richard K. Burdick, Neal Thomas, Aili Cheng   +2 more
openalex   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R.   +7 more
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core  

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study [PDF]

Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke   +4 more
openalex   +1 more source

Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching. [PDF]

JAAD Int
Aghajani M, Pham J, Sholji T, Burrell K, Kok C, Frew JW.   +5 more
europepmc   +1 more source